1168 / 1578
/
Proof of principle:
Golden Lancet Oncol 2015
Response
Abscopal response: 11/41 (26.8%)
Survival
Improved OS in responders
Ø
¼ of the patients with abscopal effect
Ø
Improved OS in patients with abscopal effect
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
33
/
• Palliative RT in 61%; SRT in only 25%
Ø
Tx-related pulmonary toxicity: (n=3) vs (n=1)
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
34
Prior RT
42 (43%)
PFS
OS
Shaverdian Lancet Oncol 2017